Harnessing biomaterial architecture to drive anticancer innate immunity

Davis, Meredith A.; Cho, Ezra; Teplensky, Michelle H.

doi:10.1039/d3tb01677c

Cited by 1 publication

(1 citation statement)

References 293 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, over the past decades, a rapid increase in early-onset cancers, defined as cancers diagnosed in adults below 50, has been observed [3,4]. Depending on the type and stage of cancer, patients are treated with traditional therapies, including surgery, chemo-, and radiotherapy, or newer forms of treatment, such as immunotherapy [5,6], targeted [7][8][9], 2 of 18 hormonal [10], gene [11], and photodynamic therapy [12]. Chemotherapy is an effective and widespread cancer treatment strategy that uses one or more cytostatic drugs.…”

Section: Introductionmentioning

confidence: 99%

Historical Perspective and Current Trends in Anticancer Drug Development

Gach-Janczak,

Drogosz-Stachowicz,

Janecka

et al. 2024

Cancers

View full text Add to dashboard Cite

Cancer is considered one of the leading causes of death in the 21st century. The intensive search for new anticancer drugs has been actively pursued by chemists and pharmacologists for decades, focusing either on the isolation of compounds with cytotoxic properties from plants or on screening thousands of synthetic molecules. Compounds that could potentially become candidates for new anticancer drugs must have the ability to inhibit proliferation and/or induce apoptosis in cancer cells without causing too much damage to normal cells. Some anticancer compounds were discovered by accident, others as a result of long-term research. In this review, we have presented a brief history of the development of the most important groups of anticancer drugs, pointing to the fact that they all have many side effects.

show abstract